IL10 and neoplasm: In our study, GPC2-CAR T cell-treated mice tolerated treatment and had elevated levels of immune-suppressive interleukin-10 in their serum after tumor clearance, though these observations in xenograft mouse models may not accurately predict on-target off-tumor toxicities in the clinic.